|
PPP2R1B expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 3.96338517560935E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
4.69679850567672E-11 |
| Normal-vs-Stage2 |
1.043799999767E-07 |
| Normal-vs-Stage3 |
1.64901425847575E-12 |
| Normal-vs-Stage4 |
1.62736490949555E-12 |
| Stage1-vs-Stage2 |
6.711800E-01 |
| Stage1-vs-Stage3 |
2.336100E-03 |
| Stage1-vs-Stage4 |
1.162030E-04 |
| Stage2-vs-Stage3 |
1.594010E-02 |
| Stage2-vs-Stage4 |
5.180100E-03 |
| Stage3-vs-Stage4 |
3.516800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
6.29107876903845E-12 |
| Normal-vs-AfricanAmerican |
5.46710000048911E-07 |
| Normal-vs-Asian |
2.26307861339592E-12 |
| Caucasian-vs-AfricanAmerican |
9.673800E-01 |
| Caucasian-vs-Asian |
2.920600E-01 |
| AfricanAmerican-vs-Asian |
5.501000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.33226762955019E-15 |
| Normal-vs-Female |
6.96154245360958E-12 |
| Male-vs-Female |
2.692400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.74171788103195E-12 |
| Normal-vs-Age(41-60Yrs) |
5.81978909508507E-13 |
| Normal-vs-Age(61-80Yrs) |
1.62725388719309E-12 |
| Normal-vs-Age(81-100Yrs) |
6.812500E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.340200E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.731900E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
5.236200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
6.863800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.938600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.823800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.842830E-03 |
| Classical-VS-Follicular |
9.863000E-01 |
| Classical-VS-Other |
8.477200E-01 |
| Classical-VS-Normal |
4.4103054541722E-11 |
| Tall-VS-Follicular |
1.122200E-02 |
| Tall-VS-Other |
3.880000E-01 |
| Tall-VS-Normal |
9.6034291630076E-14 |
| Follicular-VS-Other |
8.794000E-01 |
| Follicular-VS-Normal |
5.92029758550439E-11 |
| Other-VS-Normal |
2.955400E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
6.91668944341473E-13 |
| Normal-vs-N1 |
3.29181126801359E-13 |
| N0-vs-N1 |
2.281800E-01 |
|
|
